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Abstract
Background: The Electronic Medical Record (EMR) is a potential source for high throughput phenotyping to conduct
genome-wide association studies (GWAS), including those of medically relevant quantitative traits. We describe use of the
Mayo Clinic EMR to conduct a GWAS of red blood cell (RBC) traits in a cohort of patients with peripheral arterial disease
(PAD) and controls without PAD.
Methodology and Principal Findings: Results for hemoglobin level, hematocrit, RBC count, mean corpuscular volume,
mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration were extracted from the EMR from
January 1994 to September 2009. Out of 35,159 RBC trait values in 3,411 patients, we excluded 12,864 values in 1,165
patients that had been measured during hospitalization or in the setting of hematological disease, malignancy, or use of
drugs that affect RBC traits, leaving a final genotyped sample of 3,012, 80% of whom had $2 measurements. The median of
each RBC trait was used in the genetic analyses, which were conducted using an additive model that adjusted for age, sex,
and PAD status. We identified four genomic loci that were associated (P,5610
28) with one or more of the RBC traits
(HBLS1/MYB on 6q23.3, TMPRSS6 on 22q12.3, HFE on 6p22.1, and SLC17A1 on 6p22.2). Three of these loci (HBLS1/MYB,
TMPRSS6, and HFE) had been identified in recent GWAS and the allele frequencies, effect sizes, and the directions of effects
of the replicated SNPs were similar to the prior studies.
Conclusions: Our results demonstrate feasibility of using the EMR to conduct high throughput genomic studies of medically
relevant quantitative traits.
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Introduction
As costs of genotyping continue to drop, accurate phenotyping
is emerging as the rate-limiting step for conducting genomic
studies. Consequently, there is considerable interest in leveraging
the electronic medical record (EMR) for high-throughput
phenotyping of diseases and medically relevant traits. Repositories
of DNA from patients seen in the clinical setting can be matched
with the EMR and genotyping/sequencing conducted to identify
genetic variants associated with human diseases as well as related
quantitative traits. Such an approach may reduce the time, effort,
and cost involved in conducting genomic studies to identify disease
susceptibility loci.
In 2007, National Human Genome Research Institute
(NHGRI) funded the Electronic Medical Records and Genomics
(eMERGE) consortium to develop and implement approaches for
leveraging biorepositories with EMR systems for large-scale
genomic research, including but not limited to genome-wide
association studies (GWAS), sequencing, and structural variation
[1]. The five participating sites include Group Health Cooperative
2 University of Washington, Marshfield Clinic, Mayo Clinic,
Northwestern University, and Vanderbilt University. Each site
chose to conduct a GWAS of a primary and supplementary
phenotype. The Mayo Clinic proposal aims to identify genetic loci
associated with peripheral arterial disease (PAD) and red blood
cell (RBC) traits including hemoglobin, hematocrit, RBC count,
mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), and mean corpuscular hemoglobin concentration
(MCHC).
Disorders involving RBCs, including anemia and polycythemia,
have been associated with adverse cardiovascular outcomes as well
as hypertension and heart failure [2,3,4,5]. Prior studies indicate
that RBC traits have a substantial genetic component with
heritabilities of 0.56, 0.52, and 0.52 reported for RBC count,
MCV, and MCH, respectively [6]. A genome-wide linkage scan in
the Framingham Heart Study noted a significant linkage signal for
RBC count (chromosomes 12p13 and 19p13), MCV (chromosome
11p15), and MCH (chromosome 11p15) [6]. Recently, the results
of several GWAS for RBC traits in populations of European
ancestry were reported [7,8,9,10], with over 20 quantitative trait
loci (QTL) identified. The objective of the present study was to
assess the feasibility of leveraging the EMR to conduct a GWAS of
quantitative traits, using RBC traits as an example. We
investigated whether the QTL identified in recent GWAS of
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13011RBC traits [7,8,9,10] could be replicated using trait values derived
from the EMR. We first developed and validated an algorithm
based on billing codes and natural language processing (NLP) of
unstructured clinical notes, to exclude RBC trait values that may
have been affected by comorbidities, marrow/immune suppress-
ing medications, or major surgery. We then undertook a GWAS
for RBC traits extracted from the Mayo Clinic EMR [11].
Results
Characteristics of participants
A total of 3,487 patients (PAD cases and controls), were
recruited through 09/30/2009 for the Mayo Clinic eMERGE
study. Figure S1A illustrates the process of extraction of RBC traits
from the EMR. In total, 10 fields were extracted for each
individual (Figure S1B). After using the unique test code for each
RBC trait, as well as excluding RBC values obtained during
hospitalization, 3,411 patients remained. Since the RBC traits are
measured together as part of the complete blood count, the
number of participants and laboratory tests were similar for six
RBC traits and multiple measurements for each RBC trait were
available in most individuals (Figure S1C).
Assessment of comorbidities and medications that can
affect RBC traits
We excluded 12,864 records and 200 individuals based on the
algorithm shown in Figure 1 and described in detail in Tables S1-
S5. As a result, 3,012 genotyped patients with 20,650 values were
included in the association analyses. We selected 50 sets of RBC
trait values and performed a manual review of the EMR to assess
whether any of the exclusion criteria were present at the time of
the blood draw for these values. No exclusionary criteria were
present at the time of the blood draws, thereby validating the
algorithm. Characteristics for 3,012 individuals grouped by PAD
status are summarized in Table 1.
GWAS of RBC traits
The distribution of the number of measurements for each RBC
trait is shown in Figure S2; ,20.6% individuals had only one
laboratory test and .95% had #20 laboratory tests. For
individuals with multiple measurements, the median value was
used in the analyses, which were performed under the additive
model that adjusted for sex, age and PAD status, using PLINK
[12]. We identified 11 significant SNPs (ie, P,5610
28) within
four genomic regions that were associated with four RBC traits.
Figure 1. Algorithm for excluding RBC trait values affected by comorbidities, medications, and blood loss.
doi:10.1371/journal.pone.0013011.g001
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in Figure 2, and Manhattan plots for the QTL are shown in
Figure 3. Table 2 summarizes the chromosomal location, minor
allele (minor allele frequency), effect size by the minor allele,
variance explained by the associated loci, and P value for these
SNPs. The variance of RBC traits explained by the associated
SNPs ranged from 0.7%–2.2%.
SNPs within the intergenic region of chromosome 6q23.3
[between HBS1-like (S. cerevisiae) (HBS1L) and v-myb myeloblas-
tosis viral oncogene homolog (avian) (MYB)] were associated with
RBC count, MCV, and MCH: five SNPs with RBC count
(rs7775698 had the lowest P-value, P=1.1610
214, R
2=1.2%), six
SNPs with MCV (rs9494145 had the lowest P-value,
P=2.8610
215, R
2=2.0%) and MCH (rs7775698 had the lowest
P-value, P=5.7610
216, R
2=2.2%). These SNPs were located
within two different linkage disequilibrium (LD) blocks based on
HapMap CEU samples (Figure 4A). SNPs rs7775698, rs4895441,
rs9376092, and rs9494145 were located in the same LD block
close to HBS1L, whereas rs6569992 and rs17064262 were close to
MYB.
A nonsynonymous SNP (rs855791, VRA) within the trans-
membrane protease, serine 6 gene (TMRPSS6) on chromosome
22q12.3 was associated with MCV (P=5.4610
29, R
2=1.0%),
MCH (P=1.1610
212, R
2=1.5%), and MCHC (P=2.4610
211,
R
2=1.3%). We also noted other SNPs within this region to be
associated with MCH [rs5756504 (intronic) and rs4820268
(synonymous)] and MCHC (rs4820268). These three SNPs
showed a high level of LD (Figure 4B), suggesting that the
nonsynonymous SNP (rs855791) is the likely causal locus.
A nonsynonymous SNP (rs1800562, CRY) within the hemo-
chromatosis gene (HFE) on chromosome 6p22.1 was associated
with MCH (P=2.8610
29, R
2=1.1%) (Figure 4C). We also
identified a novel locus, rs17342717 (intronic, P=4.7610
28,
R
2=1.0%) that was associated with MCH, within solute carrier
family 17 (sodium phosphate), member 1 (SLC17A1) gene on
chromosome 6p22.2.
Replication of significant loci identified in prior GWAS for
RBC traits
We compared our results with recently reported GWAS of RBC
traits in subjects of European ancestry [7,8,9,10]. We were able to
replicate three loci identified in these studies (Table 3). The minor
allele frequencies in our study were similar to the HapMap CEU
population. The direction of allele effects was consistent across the
studies. Although the effect sizes (ie, regression coefficients) varied
Table 1. Sample characteristics.
Total (n=3,012) PAD Cases (n=1,478) Controls (n=1,534) P
Age (years) 63.269.5 65.8610.7 60.667.3 ,0.0001
Men (%) 1868 (62.0) 951 (64.3) 917 (59.8) 0.01
Body mass index (kg/m
2) 28.765.3 29.065.4 28.565.3 0.01
Hemoglobin (g/dL) 14.161.3 [13.3, 14.1, 15.0] 13.861.4 [13.0, 13.9, 14.8] 14.361.1 [13.5, 14.3, 15.1] ,0.0001
Hematocrit (%) 41.063.6 [38.7, 41.1, 43.5] 40.464.0 [37.9, 40.5, 43.1] 41.563.1 [39.3, 41.5, 43.7] ,0.0001
RBC count (610
12/L) 4.560.4 [4.3, 4.5, 4.8] 4.560.5 [4.2, 4.5, 4.8] 4.660.4 [4.3, 4,6, 4.9] ,0.0001
MCV (fL) 90.564.2 [87.9, 90.5, 93.0] 90.864.7 [87.9, 90.7, 93.6] 90.363.6 [88.0, 90.3, 92.6] 0.0007
MCH (pg) 31.161.6 [30.2, 31.1, 32.0] 31.161.8 [30.2, 31.1, 32.2] 31.161.4 [30.2, 31.1, 31.9] 0.36
MCHC (%) 34.360.5 [34.0, 34.3, 34.7] 34.360.5 [33.9, 34.3, 34.6] 34.460.5 [34.1, 34.4, 34.7] ,0.0001
Continuous variables are presented as mean 6 SD; in addition, for the six RBC traits, the [25% quartile, median, 75% quartile] is also listed; categorical variables are
presented as percentages (%).
doi:10.1371/journal.pone.0013011.t001
Figure 2. QQ plots for quantitative trait locus (QTL) analyses. The horizontal axis shows (–log10 transformed) expected P values, and the
vertical axis indicates (–log10 transformed) observed P values.
doi:10.1371/journal.pone.0013011.g002
GWA Study for RBC Traits
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e13011GWA Study for RBC Traits
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e13011across different studies, the effect sizes in our study were similar to
effect sizes in at least one of the prior studies. In order to compare
the results among different studies, we plotted the distribution of P
values and patterns of LD along these genomic regions (Figure 4).
The SNP rs4895441 within HBS1L/MYB (chromosome 6q23.3)
has been found to be associated with MCV [7], and the SNP
rs9402686 [in high LD with rs4895441 (HapMap CEU
r
2=0.953)] identified by Soranzo et al. [8] was also associated
with MCV. The SNP rs9483788 (r
2=0.602 with rs4895441)
within this genomic region was associated with RBC count [7].
These SNPs seem to be located within an LD block (Figure 4A),
close to HBS1L. In addition, we found this locus to be associated
with MCH (P=3.1610
214), a finding not observed in previous
studies.
The SNP rs855791 within TMPRSS6 (chromosomal 22q12.1)
was found to be associated with hemoglobin [7,9], MCV [10],
and MCH [9] in prior studies; it was associated with MCV
(P=5.4 610
29), MCH (P=2.8 610
29), and MCHC
(P=2.4 610
211) in the present study (Figure 4B). SNPs
rs2413450 (r
2=0.737 with rs855791) and rs5756506 (r
2=0.347
with rs855791) were also noted to be associated with MCV [7]
and MCH [8], respectively. These SNPs showed a high level
of LD.
The SNP rs1800562 within HFE (chromosomal 6p22.1) was
previously identified to be associated with hemoglobin [7],
hematocrit [7], and MCV [7,8,10]. The locus was associated with
MCV (P=5.8610
27), MCH (P=2.8610
29), and MCHC
(P=1.5610
27) in the present study. Chambers et al. [9] noted
that SNP rs198846, located in a different LD block with
rs1800562, was associated with MCV and MCH (Figure 4C).
Discussion
The EMR contains diverse and rich phenotypic information
and DNA repositories linked to the EMR allow rapid assembly of
patient sets for genomic studies. However, the utility of EMR-
based approaches for discovery or validation of genotype-
phenotype associations remains unproven. In the present study,
we demonstrate that a biorepository matched to the EMR can be
leveraged to conduct a GWAS of RBC traits. We extracted RBC
traits values over a span of 15 years from the EMR, and used a
billing code and NLP-based algorithm to exclude values that may
Table 2. Genetic variants associated with RBC traits.
Trait Chr SNP Position (bp)
Minor
allele MAF Gene b (SE) R
2 (%) P
RBC count 6q23.3 rs7775698 135,460,328 T 0.26 HBS1L/MYB 20.08660.011 1.248 1.11E-14
RBC count 6q23.3 rs4895441* 135,468,266 G 0.27 HBS1L/MYB 20.08160.011 1.105 2.46E-13
RBC count 6q23.3 rs9376092 135,468,837 A 0.27 HBS1L/MYB 20.08160.011 1.102 2.85E-13
RBC count 6q23.3 rs9494145 135,474,245 C 0.24 HBS1L/MYB 20.08060.012 1.069 7.18E-12
RBC count 6q23.3 rs6569992 135,493,845 A 0.20 HBS1L/MYB 20.07360.012 0.709 5.57E-09
MCV 6q23.3 rs7775698 135,460,328 T 0.26 HBS1L/MYB 0.91960.119 1.963 1.37E-14
MCV 6q23.3 rs4895441* 135,468,266 G 0.27 HBS1L/MYB 0.85460.118 1.723 5.03E-13
MCV 6q23.3 rs9376092 135,468,837 A 0.27 HBS1L/MYB 0.84660.118 1.695 7.94E-13
MCV 6q23.3 rs9494145 135,474,245 C 0.24 HBS1L/MYB 0.98260.124 2.022 2.82E-15
MCV 6q23.3 rs6569992 135,493,845 A 0.20 HBS1L/MYB 0.84460.133 1.285 2.50E-10
MCV 6q23.3 rs17064262 135,507,167 C 0.19 HBS1L/MYB 0.75060.136 0.977 3.49E-08
MCV 22q12.3 rs855791 35,792,882 A 0.44 TMPRSS6 20.62060.106 1.011 5.41E-09
MCH 6q23.3 rs7775698 135,460,328 T 0.26 HBS1L/MYB 0.37060.045 2.233 5.17E-16
MCH 6q23.3 rs4895441* 135,468,266 G 0.27 HBS1L/MYB 0.34360.045 1.960 3.12E-14
MCH 6q23.3 rs9376092 135,468,837 A 0.27 HBS1L/MYB 0.34060.045 1.931 4.94E-14
MCH 6q23.3 rs9494145 135,474,245 C 0.24 HBS1L/MYB 0.38060.047 2.114 1.36E-15
MCH 6q23.3 rs6569992 135,493,845 A 0.20 HBS1L/MYB 0.33360.051 1.413 7.05E-11
MCH 6q23.3 rs17064262 135,507,167 C 0.19 HBS1L/MYB 0.29560.052 1.069 1.42E-08
MCH 6p22.2 rs17342717 25,929,749 T 0.10 SLC17A1 0.37760.069 0.985 4.66E-08
MCH 6p22.1 rs1800562* 26,201,120 A 0.06 HFE 0.49460.083 1.137 2.76E-09
MCH 22q12.3 rs855791 35,792,882 A 0.44 TMPRSS6 20.28960.040 1.525 1.10E-12
MCH 22q12.3 rs5756504 35,797,216 T 0.36 TMPRSS6 0.23460.042 0.949 3.73E-08
MCH 22q12.3 rs4820268 35,799,537 G 0.47 TMPRSS6 20.26760.040 1.371 2.41E-11
MCHC 22q12.3 rs855791* 35,792,882 A 0.44 TMPRSS6 20.08460.013 1.345 2.40E-11
MCHC 22q12.3 rs4820268 35,799,537 G 0.47 TMPRSS6 20.08860.012 1.582 1.13E-12
The asterisk indicates the three replicated SNPs.
doi:10.1371/journal.pone.0013011.t002
Figure 3. Manhattan plots for GWAS analyses of RBC traits. The vertical axis indicates (–log10 transformed) observed P values; and the
horizontal line indicates the genome-wide significant level of P=5 610
28.
doi:10.1371/journal.pone.0013011.g003
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surgery. We identified 11 unique significant SNPs (P,5610
28)
within four genomic loci associated with four RBC traits. Of these,
three genomic loci (ie, HBS1L/MYB, TMPRSS6, and HFE)
recently identified as being associated with RBC traits, were
replicated, highlighting that phenotypes extracted from the EMR
can be used for GWAS of quantitative traits. The fourth genomic
locus 2 SLC17A1 2 a gene involved in sodium-phosphate co-
transport system in the kidney, is a novel locus that we found to be
associated with MCH.
Application of the GWAS approach to quantitative traits
obtained from the EMR presents several challenges [1,13]. Data
integration from the EMR often requires querying across different
data sources using different information extraction procedures
[14]. In the present study, we used several separate data sources
across the Mayo EMR (Figure S1A) to ensure the accuracy and
completeness of the RBC trait values, making it feasible to conduct
the GWAS. An additional challenge in using the EMR for
genomic studies is assessment of comorbidities and medications
that can affect the trait of interest. We used an algorithm that
combined billing codes to identify comorbidities, procedure codes
to identify surgeries associated with blood loss, and NLP to identify
relevant medications, while retaining a sufficiently large sample
size (Figure 1). We defined a time interval based on the detection
date of the corresponding codes and excluded RBC trait values
measured within this interval. Out of 35,159 RBC trait values in
3,411 patients, we excluded 12,864 values in 1,165 patients.
However, since multiple tests for RBC traits were available in the
EMR, this resulted in the exclusion of only 200 patients from the
original sample.
A remarkable aspect of our study is that we were able to identify
11 SNPs in 4 loci influencing RBC traits at a genome-wide
significance level using EMR-derived phenotypic data in only
3,012 patients. In spite of comorbidities such as chronic kidney
disease and chronic obstructive lung disease that can affect RBC
traits in PAD patients, we were able to replicate loci associated
with RBC traits in prior cohort studies. Three of the four loci had
been recently identified in GWAS that included much larger
numbers of participants. Although we did not replicate all genomic
loci from these prior studies, the loci we detected are the only ones
that were found in at least two previous studies. Our findings are
encouraging from the viewpoint of using the EMR for genomic
studies. When compared with the previous studies for RBC traits
[7,8,9,10], the directions of effect alleles were the same and the
effect sizes of the alleles were comparable to our study (Table 3).
The variance explained by the associated loci ranged from ,1%–
2%, similar to the prior studies.
The molecular functions of the four genomic regions that were
associated with RBC traits are summarized in Table 4. In addition
to regulating fetal globin expression [15], HBS1L/MYB may have
additional roles in erythropoiesis [16]. TMPRSS6 is a type II
membrane-anchored serine protease that is involved in matrix
remodeling processes in the liver [17], and is essential for normal
Figure 4. Regional plots of loci associated with RBC traits on
chromosomes 6q23.3, 22q12.3, and 6p22.1. A. Regional plots of
loci associated with RBC traits on chromosome 6q23.3: 135,450 kb –
135,520 kb. The top panel indicates the negative logarithm of observed
P value, and the bottom panel indicates the patterns of LD based on
HapMap (www.hapmap.org) CEU population. HBS1L (NM_006620) is
located from bp 135,417,715 to 135,323,216; and MYB (NM_005375) is
located from bp 135,544,146 to 135,582,002. B. Regional plots of loci
associated with RBC traits on chromosome 22q12.3: 35,791 kb –
35,840 kb. TMPRSS6 (NM_153609) is located from bp 35,791,425 to
35,829,639. Gene structure of TMPRSS6 is shown. C. Regional plots of
loci associated with RBC traits on chromosome 6p22.1: 26,195 kb –
26,216 kb. HFE (NM_000410) is located from bp 26,195,488 to
26,203,448. Gene structure of HFE is shown.
doi:10.1371/journal.pone.0013011.g004
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binding to the transferrin receptor, thereby lowering its affinity for
iron-containing transferrin and down-regulating uptake of iron by
cells [19]. SLC17A1 plays an important role in phosphate
homeostasis in animals and humans; how variants in this gene
might influence MCH needs further investigation [20]. Of note,
an intronic SNP rs17270561 (HapMap CEU r
2=0.51 with
rs17342717) within SLC17A1 was found to be associated with
transferrin saturation (P=5 610
28), by Benyamin et al [21].
Limitations
A limitation of the use of EMR in genomic studies is the
potential for selection and referral bias. Considerable effort may be
needed to develop and validate phenotyping algorithms. The
present study required a combined approach of NLP to identify
prescribed medications and billing codes to exclude RBC values
that might have been affected by chronic disease or medication
use, while capturing a sufficiently large sample size. How well the
genetic architecture of quantitative traits can be delineated from
EMR-based genomic studies may vary with the trait of interest
and will be influenced by trait heritability, variance in trait values,
and how comorbidities affect trait values. In the present study, our
ability to replicate may have been made easier by the fact that
measurement of RBC traits is relatively precise in the clinical
setting, trait values are stable over times, values may be relatively
less affected by acute phase response, and that the traits have
relatively high heritability. Additional GWAS of several quantita-
tive traits are currently in progress within the eMERGE
consortium, and will provide further insights in this regard.
Future directions
The present study lays the groundwork for a GWAS of RBC traits
across the five eMERGE sites (n=,17,000).Weanticipate detection
of additional novel genetic loci influencing RBC traits in the
consortium-wide analyses. Although the availability of multiple
measurements of a trait within the EMR may provide a more
precise estimate of the trait value as well as change in trait value over
time, it is not clear how to deal with multiple measurements in
GWASanalyses.Weareinvestigatingthestatisticalpowerofdifferent
regression methods in dealing with multiple measurements. Finally,
consistent with the goals of the eMERGE network, we are developing
phenotyping algorithms to enable EMR-based genomic studies of
other medically relevant quantitative traits and assessing the extent to
which the algorithms are portable across EMR systems.
Table 3. Comparison of the effect sizes of significant SNPs with those identified in previous GWAS for RBC traits.
Trait Gene Present study
Freq.
#
(CEU) Previous studies
SNP
Effect allele
(freq)
Effect
size (b) P SNP
Effect
allele
Effect
size (b) Ref.
MCV HBS1L/MYB rs4895441 G (0.27) 0.854 5.03E-13 0.22 rs4895441 A 20.008
* [7]
MCV HBS1L/MYB rs4895441 G (0.27) 0.854 5.03E-13 0.22 rs9402686 A 0.818 [8]
RBC count HBS1L/MYB rs4895441 G (0.27) 20.081 2.46E-13 0.22 rs9483788 T 0.014 [7]
MCV TMPRSS6 rs855791 A (0.44) 20.620 5.41E-09 0.39 rs855791 A 20.127 [10]
MCV TMPRSS6 rs855791 A (0.44) 20.620 5.41E-09 0.39 rs2413450 A 20.005 [7]
MCH TMPRSS6 rs855791 A (0.44) 20.289 1.10E-12 0.39 rs855791 A 20.330 [9]
MCH TMPRSS6 rs855791 A (0.44) 20.289 1.10E-12 0.39 rs5756506 C 0.137 [8]
MCV HFE rs1800562 A (0.06) 1.087 5.84E-07 0.04 rs1800562 A 0.222 [10]
MCV HFE rs1800562 A (0.06) 1.087 5.84E-07 0.04 rs1800562 A 0.012 [7]
MCV HFE rs1800562 A (0.06) 1.087 5.84E-07 0.04 rs1800562 A 1.408 [8]
MCV HFE rs1800562 A (0.06) 1.087 5.84E-07 0.04 rs198846 A 0.820 [9]
MCH HFE rs1800562 A (0.06) 0.494 2.76E-09 0.04 rs198846 A 0.370 [9]
*The direction of effect of rs4895441 in Ganesh et al. [7] is based on the major allele (A) instead of the minor allele (G).
#: Frequency of effect allele (the present study) in the HapMap CEU population.
doi:10.1371/journal.pone.0013011.t003
Table 4. Molecular function of associated loci.
Symbol Chr. Gene Function Ref.
HBS1L/MYB 6q23.3 HBS1-like/v-myb myeloblastosis viral oncogene
homolog (avian)
Regulates fetal globin expression [15]
TMPRSS6 22q12.3 transmembrane protease, serine 6 Acts by cleaving hemojuvelin* [26]
HFE 6p22.1 hemochromatosis protein isoform 1 precursor Binds tightly to transferrin receptor 1, and
reduces binding of transferring
[19]
SLC17A1 6p22.2 solute carrier family 17 (sodium phosphate),
member 1
Essential for phosphate homeostasis in
animals and humans
[20]
*hemojuvelin is essential for production of the iron regulatory hormone hepcidin [27].
doi:10.1371/journal.pone.0013011.t004
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genetic loci associated with inter-individual variation in RBC traits
in prior cohort studies. As genotyping costs continue to decrease,
phenotyping is emerging as the major bottleneck for identifying
genetic loci influencing disease susceptibility or variation in
medically relevant quantitative traits. Mining of the EMR is a
high throughput, relatively inexpensive method to facilitate genetic
studies of quantitative traits. Increasing use of the EMR affords an
opportunity to expedite the investigation of genetic architecture of
common and rare diseases as well as quantitative traits of medical
importance.
Materials and Methods
Study participants
In October 2006, a biorepository of plasma and DNA samples
was initiated by recruiting patients referred for lower extremity
arterial evaluation to the Mayo Clinic’s non-invasive vascular
laboratory and individuals referred to the stress ECG laboratory to
screen for coronary artery disease. Between October 2006 and
May 2009, 3,527 patients were recruited. We used the following
criteria to define presence of PAD: 1) an ankle brachial index (ABI)
#0.9 at rest or 1 min after exercise; or 2) presence of poorly
compressible arteries; or 3) normal ABI but prior history of
revascularization for PAD [22]. All participants gave their written
informed consent for participation in the study and the use of their
data for future research. The study protocol was approved by the
Institutional Review Board of the Mayo Clinic. The Mayo EMR
began accumulating data in the early 1990s [23] and now includes
all inpatient and outpatient billing codes, laboratory values,
reports, and clinical documentation, almost all in electronic
formats available for searching [11]. It currently contains over 120
million documents on ,2 million patients. Patient-level data
elements in the Mayo EMR included demographics, outpatient
visits and hospitalizations, providers, diagnosis and procedure
codes, and RBC trait values. Birth date, race, sex, ethnicity were
obtained from the demographic database; the categories for race
were ‘White,’ ‘Black or African American,’ ‘Hispanic,’ ‘Asian/
Pacific Islander,’ ‘American Indian/Alaskan Native,’ ‘Others,’
‘Unknown,’ and ‘Choose not to disclose.’
RBC traits
The complete blood count is a commonly performed laboratory
test [24] and includes the following RBC traits: (1) hemoglobin
level: the concentration of hemoglobin within whole blood; (2)
hematocrit, the percentage of whole blood comprising cellular
erythrocyte elements; (3) RBC count, the number of red blood
cells per volume of blood; (4) mean corpuscular volume (MCV),
the average erythrocyte volume; (5) mean corpuscular hemoglobin
(MCH), the average mass of hemoglobin per RBC in a sample of
blood; and (6) mean corpuscular hemoglobin concentration
(MCHC), the concentration of hemoglobin in a given volume of
packed RBC.
Data integration from the EMR
To extract data for RBC traits, we used separate relational
databases as well as semi-structured data sources in the Mayo
EMR. A schematic depicting extraction of RBC traits from the
EMR is shown in Figure S1A. The data extracted for the period
01/01/1994 to 09/30/2009 included the test code and
description, date and time of sample, units of results, associated
reference range and indicators for low/high results, lab accession
number, and results of the test in both character and numeric
format (Figure S1B). Any RBC trait values obtained during an
inpatient hospitalization (admit date#sample date#discharge
date) were excluded unless these were only tests available for a
patient.
Assessment of comorbidities and medications that can
affect RBC traits
Since RBC traits are affected by a wide array of medical
conditions, we developed an EMR-based algorithm that includes
billing codes and NLP of unstructured clinical notes to exclude
values affected by comorbidities, medications or blood loss
(Figure 1, and Tables S1-S5 and Methods S1). We compiled the
International Classification of Disease 9 Clinical Management
(ICD-9 CM), procedural ICD-9, and Current Procedural
Terminology (CPT-4) codes indicative of clinical conditions
that may affect RBC traits. The medical conditions included
hematologic and solid-organ malignancies, bone marrow and
solid-organ transplantation, cirrhosis, hereditary anemias, and
malabsorption disorders. The medications included chemothera-
peutic and immunosuppressive drugs. The algorithm is described
in detail in the supplementary materials. Out of 35,159 RBC trait
values in 3,411 patients, we excluded 12,864 values (in 1,165
patients) that had been measured during hospitalization or in the
setting of hematological disease, malignancy, or use of drugs that
affect RBC traits. As a result, 200 patients were excluded from the
analyses.
Association analyses
We used the median of a trait value when multiple results were
available. Genotyping was performed at the Center for Genotyp-
ing and Analysis at the Broad Institute, using the Illumina
Human660W-Quadv1_A genotyping platform, consisting of
561,490 SNPs and 95,876 intensity-only probes. Data were
cleaned using the quality control (QC) pipeline developed by the
eMERGE Genomics Working Group. This process includes
evaluation of sample and marker call rate, gender mismatch and
anomalies, duplicate and HapMap concordance, batch effects,
Hardy-Weinberg equilibrium, sample relatedness, and population
stratification. A total of 489,421 SNPs were used for analysis based
on the following QC criteria: SNP call rate .98%, sample call rate
.98%, minor allele frequency .0.05, Hardy-Weinberg equilib-
rium .0.001, 99.99% concordance rate in duplicates, and
unrelated samples only. We excluded 11 samples with labeling
errors. The data from all the patients, in addition to the HapMap
III populations, were evaluated for population structure/substruc-
ture using EIGENSTRAT software [25], and those who were not in
the European cluster were excluded (n=42). After QC steps, 3,012
samples with phenotype and genotype data were available for
association analyses (Figure S3).
Single-locus tests of association were performed in PLINK using
linear regression analysis that assumed an additive genetic model
and incorporated age, sex, and PAD case-control status as
covariates [12]. To assess population structure, we examined the
genomic control inflation factor (lGC) for six RBC traits, and
found these values to be below 1.020 without systematic inflation:
1.014 (hemoglobin), 1.017 (hematocrit), 1.007 (RBC count), 1.007
(MCV), 1.004 (MCH), and 1.016 (MCHC). After correcting for
population structure using lGC, the significant loci identified in the
present study remained at P,5610
28. The power of our study
was ,85% to detect a QTL that explains 1.5% variance in an
RBC trait, given a sample size of 3,000, a minor allele frequency of
0.05, and the significance level of 5610
28. The data for the
consortium-wide analyses of RBC indices will be uploaded to
dbGAP (www.ncbi.nlm.nih.gov/gap).
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Figure S1 A. Schematic diagram of extracting data of RBC
parameters from the EMR. B. The structure of extraction data
from the EMR. Test description is the six RBC traits. C. Summary
of the RBC traits in the extraction data. MCV, mean corpuscular
volume; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration.
Found at: doi:10.1371/journal.pone.0013011.s001 (2.56 MB TIF)
Figure S2 Bar chart of the number of laboratory tests for RBC
traits. MCV, mean corpuscular volume; MCH, mean corpuscular
hemoglobin; MCHC, mean corpuscular hemoglobin concentra-
tion.
Found at: doi:10.1371/journal.pone.0013011.s002 (0.24 MB TIF)
Figure S3 A flow chart of quality control of phenotypic and
genotypic data for RBC traits in GWA studies.
Found at: doi:10.1371/journal.pone.0013011.s003 (2.30 MB TIF)
Methods S1 Assessment of comorbidities and medications that
can affect RBC traits.
Found at: doi:10.1371/journal.pone.0013011.s004 (0.04 MB
DOC)
Table S1 ICD-9-CM codes indicating the most commonly
disorders that may affect RBC traits.
Found at: doi:10.1371/journal.pone.0013011.s005 (0.09 MB
DOC)
Table S2 ICD-9 and CPT-4 procedural codes indicating bone
marrow and/or solid organ transplantation.
Found at: doi:10.1371/journal.pone.0013011.s006 (0.05 MB
DOC)
Table S3 CPT-4 codes indicating medications.
Found at: doi:10.1371/journal.pone.0013011.s007 (0.04 MB
DOC)
Table S4 Generic and brand names of commonly used oral
chemotherapeutic and immunosuppressive medications.
Found at: doi:10.1371/journal.pone.0013011.s008 (0.05 MB
DOC)
Table S5 CPT-4 codes indicating anesthesia codes for surgeries
that are likely to be associated with major blood loss and post-
operative anemia.
Found at: doi:10.1371/journal.pone.0013011.s009 (0.09 MB
DOC)
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